Summit: FDA sets Nob 14, 2026 PDUFA for ivonescimab BLA in EGFRm NSCLC

Sipi mula sa source

EX-99.1 2 a2026_prx0723xq22026earn.htm EX-99.1 a2026_prx0723xq22026earn Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 Consistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy Ivonescimab Plus Chemotherapy Achieves Statistically Significant and Clinically Meaningful Overall Survival Benefit in 1L Squamous NSCLC HARMONi-6 Trial Conducted in China, the First Phase III Head-to-Head Clinical Study to Demonstrate Superiority over an Anti-PD-(L)1 Antibody-Containing Regimen HARMONi-3 Global Phase III 1L NSCLC Study: Squamous Cohort Final PFS Analysis Events Expected to Be Reac

SEC 8-K

Higit pa tungkol sa asset na ito

Okt 28, 2026

03:22 PM

SMMTSummit Therapeutics

ivonescimab · NCT07158489 update sa rehistro

Pagbabago sa trial registryClinicalTrials.gov

Okt 23, 2026

08:37 PM

SMMTSummit Therapeutics

Sumasama ang Summit Therapeutics sa Lunit upang gamitin ang AI-powered na SCOPE IO para sa pagsusuri ng ivonescimab TME

Partnership / kasunduan sa lisensyaPress release ng kumpanyaBuksan ang record1 update

Okt 22, 2026

10:00 AM

SMMTSummit Therapeutics

Ipapakita ng Summit Therapeutics ang Data ng Ivonescimab sa 10 Abstract sa ESMO 2026

Presentasyon sa kumperensyaPress release ng kumpanya

Okt 21, 2026

08:42 PM

SMMTSummit Therapeutics

Nakipagtulungan ang Summit Therapeutics at ECOG-ACRIN sa Phase II/III EA2251 Trial ng Ivonescimab sa First-Line BTC

Pagbabago sa trial registryPress release ng kumpanyaBuksan ang record2 update

Okt 19, 2026

11:00 AM

SMMTSummit Therapeutics

Binuksan ng Summit Therapeutics ang Phase II SMT112-216 na pagsubok ng mga regimen ng ivonescimab sa 1L advanced ccRCC

Pagbabago sa trial registryPress release ng kumpanya1 update

Okt 8, 2026

03:22 PM

SMMTSummit Therapeutics

ivonescimab · NCT05899608 update sa rehistro

Pagbabago sa trial registryClinicalTrials.govBuksan ang record

Okt 6, 2026

03:21 PM

SMMTSummit Therapeutics

ivonescimab · NCT07228832 update sa rehistro

Pagbabago sa trial registryClinicalTrials.gov

Okt 5, 2026

11:00 AM

SMMTSummit Therapeutics

Isinara ng Summit Therapeutics ang $2B na Pamumuhunan sa Equity ng AstraZeneca para sa Ivonescimab

Partnership / kasunduan sa lisensyaPress release ng kumpanyaBuksan ang record1 update

Okt 2, 2026

03:22 PM

SMMTSummit Therapeutics

ivonescimab · NCT07244978 update sa rehistro

Pagbabago sa trial registryClinicalTrials.govBuksan ang record

Okt 2, 2026

06:30 AM

SMMTSummit Therapeutics

Pumasok si Summit Therapeutics sa pakikipagtulungan sa klinikal na pagsubok kasama ang AstraZeneca at Daiichi Sankyo para sa ivonescimab + Datroway

Partnership / kasunduan sa lisensyaPress release ng kumpanyaBuksan ang record